Navigation Links
Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Date:10/27/2008

SEATTLE, Oct. 27 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced positive data from a Phase 1/2a study demonstrating that repeat administration with TRU-015 continues to produce persistent responses and significant improvements in rheumatoid arthritis (RA) signs and symptoms based on American College of Rheumatology (ACR) criteria. Trubion also announced positive results following preliminary analyses from a Phase 2b study in which patients have received one course of re-treatment with 800 mg of TRU-015. TRU-015 is being developed by Wyeth Pharmaceuticals in collaboration with Trubion.

TRU-015 Phase 1/2a Re-treatment Data: Re-treatment Administered Every 24 Weeks for 2 Years Produces Well-Tolerated and Consistent Results

Re-treatment data from the Phase 1/2a study (15001) were presented on Oct. 26, 2008, in a poster session at the ACR 2008 Annual Meeting in San Francisco. Patients treated with a single course of TRU-015 at 5 mg/kg or higher in a previously conducted Phase 1/2a study (15001) were eligible for re-treatment. Patients given an initial dose of 5 mg/kg received a single infusion of 5 mg/kg upon re-treatment and those given higher doses of TRU-015 received a single infusion of 15 mg/kg upon re-treatment. Patients were eligible for repeat therapy at 24-week intervals.

Thirty-eight patients entered the Phase 1/2a re-treatment study; some patients have received as many as seven courses of TRU-015 at the time of this assessment. At 24 weeks, ACR 20, 50 and 70 response rates for 18 patients that have received their third re-treatment with 5 mg/kg or 15 mg/kg TRU-015 were 50%, 17% and 11%, respectively. Ongoing patient evaluations demonstrated maintenance of ACR responses foll
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
2. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
3. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
4. Trubion Announces Presentations at April/May Investor Conferences
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
7. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
10. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
11. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Selexis SA , ... drug discovery and mammalian cell line development, announced today ... ™ will be presented at the 10th Annual ... September 8 – 10, 2014 at the Double Tree ... The following abstract will be presented during an oral ...
(Date:7/30/2014)... July 30, 2014   Wyle has ... Integrated Lifecycle Mission Support Services (FILMSS) contract awarded ... Under the terms of the contract, Wyle will ... Moffett Field, Calif. In particular, Wyle will provide ... development projects on the International Space Station and ...
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
(Date:7/30/2014)... Vycom announces the addition of Thermax ... meet Factory Mutual (FM) 4910 fire propagation and smoke ... benches, process tools, fume hoods, furniture and cabinetry. These ... semiconductor wafers used in electronic chip manufacturing. , ... with excellent workability and superior aesthetics. It is available ...
Breaking Biology Technology:Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2
... /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals (NASDAQ: OGXI ) announced ... Fast Track designation from the U.S. Food & ... prostate cancer. OGX-011 is currently completing five Phase ... and is designed to,inhibit the production of a ...
... 21 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RVX) is pleased ... on August 25, 2008 at 11:00 am MDT ... the presentation there will be a live,question and ... at the following link:, http://services.choruscall.com/links/resverlogix080825.html , ...
... BPUR ) today announced its financial results for the ... the company reported a net,loss of $4.6 million, or ... $6.4 million, or $0.41 per common share, for the ... July 31, 2008 and 2007 were,37,340,051 and 15,592,025, respectively., ...
Cached Biology Technology:FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 3FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 4Resverlogix Notice of Conference Call & Webcast 2Biopure Announces 2008 Third Quarter Financial Results 2Biopure Announces 2008 Third Quarter Financial Results 3Biopure Announces 2008 Third Quarter Financial Results 4Biopure Announces 2008 Third Quarter Financial Results 5Biopure Announces 2008 Third Quarter Financial Results 6Biopure Announces 2008 Third Quarter Financial Results 7
(Date:7/31/2014)... University researcher found that bacteria in the Gulf of ... oil released during the Deepwater Horizon spill in the ... contaminants. , In two new studies conducted in a ... species of bacteria called Colwellia likely consumed ... compounds that were released as part of the oil ...
(Date:7/31/2014)... that marine noise can affect animal movement and communication, ... Bristol and Exeter and the cole Pratique des Hautes ... noise stops embryonic development and increases larval mortality in ... Stylocheilus striatus used in this study) usually ... feed on toxic alga but this study, conducted in ...
(Date:7/30/2014)... in Lewis Carroll,s Through the Looking Glass, collaborators ... of Singapore improved a 35-year-old ecology model to ... millions of years. , The new model, called ... "Red Queen Effect," an evolutionary hypothesis introduced by ... that organisms must constantly increase their fitness (or ...
Breaking Biology News(10 mins):Boat noise impacts development and survival of sea hares 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... produced by the body. It cannot regenerate itself, because it ... by the time the tooth appears in the mouth. The ... damage, and decay. For this reason, it is exciting to ... teeth, using culturing and transplantation techniques. In the emergent field ...
... cancers, researchers from Whitehead Institute and Massachusetts Institute of Technology ... MicroRNAs are tiny snippets of RNA that can repress activity ... copies DNA information and starts the process of protein production). ... in worms. It took seven years for the second one ...
... promising alternative for the reconstitution of lost ... complications associated with traditional transplants. Tissue engineers ... by using engineered tissue substitutes that can ... into the host tissue. The traditional tissue-engineering ...
Cached Biology News:Scientists re-grow dental enamel from cultured cells 2MicroRNA helps prevent tumors 2MicroRNA helps prevent tumors 3
...
... PlusOne Silver Staining Kit, Protein, 1. ... and Dernick (1), the kit gives ... electrophoresis systems.Silver Staining Kit, Protein provides ... proteins in polyacrylamide gels in less ...
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
Cyno macaque plasma and serum - various quantities available...
Biology Products: